Aetiology and pathogenesis of benign prostatic hyperplasia
- PMID: 12490809
- DOI: 10.1097/00042307-200301000-00002
Aetiology and pathogenesis of benign prostatic hyperplasia
Abstract
Purpose of review: Prostatic hyperplasia predominantly involves the stromal compartment of the gland and affects more than 70% of men of 70 years or older with or without obstructive symptoms of benign prostatic hyperplasia. A consensus view is emerging concerning the factors and control systems that modulate cell proliferation and connective tissue biology in the prostate. The purpose of this review is to discuss some of the recent work contributing to the latter in the context of the aetiology of benign prostatic hyperplasia.
Recent findings: Studies over the last 3-5 years have identified transforming growth factor beta, fibroblast growth factor and insulin-like growth factor family members as key regulators of cell proliferation and extracellular matrix turnover with interrelated activities. Recently, oestrogens, adrenergic signalling and inflammatory processes have been shown to impact and potentially perturb the balance between the activities of the above factors. These agents are all subject to alteration with age and as such are candidates for potential triggers of the initiation of stromal hyperplasia.
Summary: The current model for the control and dysregulation of prostatic stromal growth is discussed in relation to the pathogenesis of benign prostatic hyperplasia and future directions for research.
Similar articles
-
The pathophysiology of benign prostatic hyperplasia.Drugs Today (Barc). 2002 Dec;38(12):867-76. doi: 10.1358/dot.2002.38.12.740205. Drugs Today (Barc). 2002. PMID: 12582474 Review.
-
Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-beta.Front Biosci. 2003 Sep 1;8:s740-9. doi: 10.2741/1093. Front Biosci. 2003. PMID: 12957826 Review.
-
Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFbeta).Prostate. 1999 Oct 1;41(2):110-20. doi: 10.1002/(sici)1097-0045(19991001)41:2<110::aid-pros5>3.0.co;2-x. Prostate. 1999. PMID: 10477907
-
Apoptotic versus proliferative activities in human benign prostatic hyperplasia.Hum Pathol. 1996 Jul;27(7):668-75. doi: 10.1016/s0046-8177(96)90396-2. Hum Pathol. 1996. PMID: 8698310
-
Benign prostatic hyperplasia: age-related tissue-remodeling.Exp Gerontol. 2005 Mar;40(3):121-8. doi: 10.1016/j.exger.2004.12.008. Epub 2005 Jan 22. Exp Gerontol. 2005. PMID: 15763388 Review.
Cited by
-
Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis.Front Physiol. 2017 Sep 12;8:688. doi: 10.3389/fphys.2017.00688. eCollection 2017. Front Physiol. 2017. PMID: 28955247 Free PMC article.
-
Management of experimental benign prostatic hyperplasia in rats using a food-based therapy containing Telfairia occidentalis seeds.Afr J Tradit Complement Altern Med. 2011;8(4):398-404. doi: 10.4314/ajtcam.v8i4.9. Epub 2011 Jun 1. Afr J Tradit Complement Altern Med. 2011. PMID: 22654217 Free PMC article.
-
Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.Am J Clin Exp Urol. 2022 Jun 15;10(3):154-169. eCollection 2022. Am J Clin Exp Urol. 2022. PMID: 35874288 Free PMC article. Review.
-
Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):389-395. doi: 10.1007/s11596-012-0067-x. Epub 2012 Jun 9. J Huazhong Univ Sci Technolog Med Sci. 2012. PMID: 22684563
-
Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model.PLoS One. 2017 May 30;12(5):e0178152. doi: 10.1371/journal.pone.0178152. eCollection 2017. PLoS One. 2017. PMID: 28558037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials